Targeted-release budesonide for treating primary IgA nephropathy (review of TA937) [ID6485]

Status:

In progress

Technology type:

Medicine

Decision:

Selected

Reason for decision:

Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources

Process:

STA Standard

ID number:

6485

Provisional Schedule

Committee meeting:

14 October 2025

Expected publication:

17 December 2025

Project Team

Project lead

Leena Issa

Email enquiries

If you have any queries please email [email protected]

External Assessment Group:

Southampton Health Technology Assessment Centre (SHTAC), University of Southampton

Stakeholders

Companies sponsors

Genus Pharmaceuticals (targeted-release budesonide)

Others

Department of Health and Social Care

 

NHS England

Patient carer groups

Kidney Care UK

 

Kidney Research UK

Professional groups

Royal College of Physicians

 

UK Kidney Association

 

UK Renal Pharmacy Group

Associated public health groups

None

Comparator companies

Boehringer Ingelheim (empagliflozin, telmisartan) (confidentiality agreement signed, participating)

 

Novartis (valsartan) (confidentiality agreement signed, participating)

 

Takeda (azilsartan) (confidentiality agreement signed, participating)

 

Vifor Pharma (sparsentan) (confidentiality agreement signed, participating)

 

A.Menarini Group (canagliflozin) (confidentiality agreement not signed, not participating)

 

Advanz pharma (acetazolamide) (confidentiality agreement not signed, not participating)

 

Amarox (eprosartan, irbesartan, losartan, olmesartan) (confidentiality agreement not signed, not participating)

 

AS Kalceks (furosemide) (confidentiality agreement not signed, not participating)

 

AstraZeneca (dapagliflozin) (confidentiality agreement not signed, not participating)

 

Atnahs pharma (chlortalidone, lisinopril) (confidentiality agreement not signed, not participating)

 

Aurobindo pharma (amiloride hydrochloride, candesartan, enalapril, furosemide, fosinopril, irbesartan, lisinopril, losartan, olmesartan, perindopril, ramipril, valsartan) (confidentiality agreement not signed, not participating)

 

Baxter healthcare ( furosemide) (confidentiality agreement not signed, not participating)

 

Bristol laboratories (lisinopril) (confidentiality agreement not signed, not participating)

 

Brown & Burk (irbesartan, lisinopril, ramipril, telmisartan, losartan) (confidentiality agreement not signed, not participating)

 

Chemidex pharma (amiloride hydrochloride, bumetanide) (confidentiality agreement not signed, not participating)

 

Daiichi Sankyo (olmesartan) (confidentiality agreement not signed, not participating)

 

Dexcel pharma (enalapril, losartan) (confidentiality agreement not signed, not participating)

 

Essential pharma (amiloride hydrochloride) (confidentiality agreement not signed, not participating)

 

Flamingo Pharma (losartan) (confidentiality agreement not signed, not participating)

 

Glenmark pharma (olmesartan, perindopril, telmisartan) (confidentiality agreement not signed, not participating)

 

Hameln pharma (furosemide) (confidentiality agreement not signed, not participating)

 

Ipca laboratories (furosemide) (confidentiality agreement not signed, not participating)

 

KrKA UK (candesartan, indapamide, losartan, olmesartan, perindopril, telmisartan) (confidentiality agreement not signed, not participating)

 

Martindale pharma (captopril) (confidentiality agreement not signed, not participating)

 

Merck Sharp & Dohme (ertugliflozin) (confidentiality agreement not signed, not participating)

 

Morningside healthcare (chlortalidone) (confidentiality agreement not signed, not participating)

 

Neon healthcare (candesartan) (confidentiality agreement not signed, not participating)

 

Organon Pharma (enalapril, losartan) (confidentiality agreement not signed, not participating)

 

Pfizer (quinapril) (confidentiality agreement not signed, not participating)

 

Phoenix healthcare (quinapril) (confidentiality agreement not signed, not participating)

 

Pinewood healthcare (furosemide) (confidentiality agreement not signed, not participating)

 

Proveca (enalapril) (confidentiality agreement not signed, not participating)

 

Roma pharmaceuticals (lisinopril, ramipril) (confidentiality agreement not signed, not participating)

 

Rosemont pharmaceuticals (bumetanide, enalapril, furosemide, lisinopril, ramipril) (confidentiality agreement not signed, not participating)

 

Sandoz (candesartan, losartan, perindopril, ramipril, telmisartan) (confidentiality agreement not signed, not participating)

 

Sanofi (furosemide, irbesartan, ramipril) (confidentiality agreement not signed, not participating)

 

Servier laboratories (indapamide, perindopril) (confidentiality agreement not signed, not participating)

 

Sigma pharmaceuticals (amiloride hydrochloride, bendroflumethiazide, chlortalidone, indapamide, quinapril) (confidentiality agreement not signed, not participating)

 

Strides pharma (furosemide, indapamide) (confidentiality agreement not signed, not participating)

 

Ten pharma (captopril) (confidentiality agreement not signed, not participating)

 

Thame laboratories (captopril, furosemide) (confidentiality agreement not signed, not participating)

 

Thornton & Ross (olmesartan) (confidentiality agreement not signed, not participating)

 

Tillomed laboratories (amiloride hydrochloride, perindopril,) (confidentiality agreement not signed, not participating)

 

Viatris (bendroflumethiazide, bumetanide, candesartan, enalapril, eprosartan, indapamide, irbesartan, lisinopril, losartan, perindopril, torasemide, trandolapril, valsartan, xipamide) (confidentiality agreement not signed, not participating)

 

Wockhardt UK (amiloride hydrochloride, captopril, chlortalidone, furosemide, ramipril) (confidentiality agreement not signed, not participating)

 

Zentiva (indapamide, irbesartan, ramipril, valsartan) (confidentiality agreement not signed, not participating)

General commentators

All Wales Therapeutics and Toxicology Centre

 

British National Formulary

 

Department of Health - Northern Ireland

 

Healthcare Improvement Scotland

 

Medicines and Healthcare products Regulatory Agency

 

NHS Wales Joint Commissioning Committee

 

Scottish Medicines Consortium

 

Welsh Government

Relevant research groups

None

Related links

• NIHRIO briefing

Timeline

Key events during the development of the guidance:

For further information on our processes and methods, please see our CHTE processes and methods manual